Steven Quayle
Senior Vice President & Head of Research & Translational Medicine Cue Biopharma
Steven Quayle, PhD, is Senior Vice President and Head of Research and Translational Medicine at Cue Biopharma, where he leads the discovery and development of precision immunotherapeutics. Since joining Cue in 2017, he has advanced novel biologics for antigen-specific T-cell modulation across research and clinical programs. Previously, Dr. Quayle held leadership roles in oncology and translational biology at KDAc Therapeutics and Acetylon Pharmaceuticals and conducted postdoctoral research at Dana-Farber Cancer Institute. He earned his PhD in Pathology and Laboratory Medicine and his BSc in Cell Biology from the University of British Columbia, focusing on cancer biology and immunology.
Seminars
Key Discussion Points:
- Innovative engineering of CUE-401 enables dual agonism of IL-2 and TGF-β for the induction of regulatory T cells
- First-in-class CUE-401 mechanism is differentiated from other classes of Treg-directed therapies
- Translational studies support broad therapeutic opportunities across diverse indications
